Scarica l'app Stockscreener
59.87
0.12%
-0.07
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
LSV Asset Management Purchases 812,284 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com Nigeria
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights
BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView
BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com UK
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Why BioMarin Pharmaceutical Inc. stock is a must watch in 2025Trade Exit Summary & Verified Momentum Watchlists - mfd.ru
Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Newswire Canada
BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is BioMarin Pharmaceutical (BMRN) Now Trading Below Its Long Term Prospects - Sahm
Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz
BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI
BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Mediolanum International Funds Ltd - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat
Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz
BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India
BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility - Chartmill
Hussman Strategic Advisors Inc. Takes $1.14 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - simplywall.st
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):